ORIGINAL PAPER
Adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in therapeutic programmes – personal experience
Online publication date: 2013-03-05
Reumatologia 2013;51(1):9-14
KEYWORDS
ABSTRACT
The objective of the study was to investigate the effects and safety of adalimumab (ADA) therapy in the national therapeutic programme, in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA).
Material and methods: The process of ADA therapy was analysed in 41 patients (24 RA, 11 AS, 6 PsA). Patients were qualified, according to the rules of the therapeutic programme of the National Health Service, due to high disease activity, despite previous treatment. Monitoring of patients was performed according to the requirements of the therapeutic programme. ADA was given subcutaneously 40 mg every other week.
Results: In the RA group, an adequate response to therapy was observed in 13 patients (54.2%): remission in 8 (33.3%) and low disease activity in 5 (20.9%), which continued in 5 patients after ADA cessation, for a mean of 4.5 months. Primary inefficacy after 3 months of therapy (lack of adequate response) was observed in 4 (16.7%), after 6 months of therapy (lack of remission/low disease activity) in 10 (41.7%). During remission/low activity period, exacerbation of RA was observed in 6/13 patients; in 2/13 secondary inefficacy was observed.
In the AS group, in 1 patient (9.1%) primary inefficacy was observed. In 10 (90.9%) low disease activity was achieved in 9 patients (90.9%), which continued for a mean of 5.4 months. During the improvement period, after cessation of ADA, 8/10 patients experienced exacerbation; secondary inefficacy was observed in 1/10 patients. In the PsA group, low disease activity was achieved in 5 patients (83.3%) during ADA administration; in 1 (16.7%) primary inefficacy was observed. In all treated patients, adverse events were noted in 17/41 (41.5%): infections (urinary, respiratory tract, viral), injection site reactions. They resulted in cessation of ADA therapy in 5 patients (4 RA patients and 1 AS patient). The number of adequate responses to ADA treatment was statistically significantly higher in AS than in RA patients (p = 0.04).
Conclusions: Treatment of ADA is a safe and effective form of therapy in patients with RA, AS and PsA, those with persistent high disease activity and non-responders to previous therapy.
Material and methods: The process of ADA therapy was analysed in 41 patients (24 RA, 11 AS, 6 PsA). Patients were qualified, according to the rules of the therapeutic programme of the National Health Service, due to high disease activity, despite previous treatment. Monitoring of patients was performed according to the requirements of the therapeutic programme. ADA was given subcutaneously 40 mg every other week.
Results: In the RA group, an adequate response to therapy was observed in 13 patients (54.2%): remission in 8 (33.3%) and low disease activity in 5 (20.9%), which continued in 5 patients after ADA cessation, for a mean of 4.5 months. Primary inefficacy after 3 months of therapy (lack of adequate response) was observed in 4 (16.7%), after 6 months of therapy (lack of remission/low disease activity) in 10 (41.7%). During remission/low activity period, exacerbation of RA was observed in 6/13 patients; in 2/13 secondary inefficacy was observed.
In the AS group, in 1 patient (9.1%) primary inefficacy was observed. In 10 (90.9%) low disease activity was achieved in 9 patients (90.9%), which continued for a mean of 5.4 months. During the improvement period, after cessation of ADA, 8/10 patients experienced exacerbation; secondary inefficacy was observed in 1/10 patients. In the PsA group, low disease activity was achieved in 5 patients (83.3%) during ADA administration; in 1 (16.7%) primary inefficacy was observed. In all treated patients, adverse events were noted in 17/41 (41.5%): infections (urinary, respiratory tract, viral), injection site reactions. They resulted in cessation of ADA therapy in 5 patients (4 RA patients and 1 AS patient). The number of adequate responses to ADA treatment was statistically significantly higher in AS than in RA patients (p = 0.04).
Conclusions: Treatment of ADA is a safe and effective form of therapy in patients with RA, AS and PsA, those with persistent high disease activity and non-responders to previous therapy.
REFERENCES (17)
1.
Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2012 doi:10.1136/annrheumdis-2011-201244.
2.
Poddubnyy D, Rudwaleit M. Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Expert Opin Drug Saf 2011; 10: 655-673.
3.
Rudwaleit M, Van den Bosch F, Kron M, et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 2010; 12: R117.
4.
Burmester GR, Mariette X, Montecucco C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007; 66: 732-739.
5.
Weinblatt ME, Keystone EC, Furst DE, et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006; 65: 753-759.
6.
Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-αntagonist therapy in clinical practice. Rheumatology (Oxford) 2007; 46: 1191-1199. .
7.
Hjardem E, Ostergaard M, Podenphant J, et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis 2007; 66: 1184-1189.
8.
Van der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 2010; 37: 2237-2246.
9.
Revicki DA, Luo MP, Wordsworth P, et al. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J Rheumatol 2008; 35: 1346-1353.
10.
Rudwaleit M, Claudepierre P, Kron M, et al. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Arthritis Res Ther 2010; 12: R43.
11.
Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009; 68: 702-709.
12.
Paccou J, Baclé-Boutry MA, Solau-Gervais E, et al. Dosage Adjustment of Anti-Tumor Necrosis Factor- Inhibitor in Ankylosing Spondylitis Is Effective in Maintaining Remission in Clinical Practice. J Rheumatol 2012; 39: 1418-1423.
13.
Ornbjerg LM, Ostergaard M, Bo/yesen P, et al. Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2012 doi:10.1136/annrheumdis-2012-201319.
14.
Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315- 324.
15.
Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-368. .
16.
Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-2673.
17.
Programy lekowe. Obwieszczenie Ministra Zdrowia z dnia 28 czerwca 2012 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na dzień 1 lipca 2012 r. (załączniki: B.33, B.35, B.36).
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
